Kathryn Romano, Chief Accounting Officer at Krystal Biotech, Inc. (KRYS), sold 68,056 shares at $110.00 ($7.0M) on 2023-05-22, disclosed to the SEC on 2023-05-23.
Scheduled sale ($7.0M) by Chief Accounting Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $95.04 | 12,500 | $1.2M | 17.1% |
| 2 | $95.05 | 12,500 | $1.2M | 17.1% |
| 3 | $95.08 | 3,428 | $326K | 4.7% |
| 4 | $95.08 | 3,428 | $326K | 4.7% |
| 5 | $105.80 | 2,521 | $267K | 3.8% |
| 6 | $105.80 | 2,521 |
| $267K |
| 3.8% |
| 7 | $106.81 | 2,570 | $275K | 3.9% |
| 8 | $106.81 | 2,570 | $275K | 3.9% |
| 9 | $107.88 | 1,300 | $140K | 2.0% |
| 10 | $109.17 | 2,955 | $323K | 4.6% |
| 11 | $109.17 | 2,955 | $323K | 4.6% |
| 12 | $109.99 | 3,154 | $347K | 5.0% |
| 13 | $109.99 | 3,154 | $347K | 5.0% |
| 14 | $110.00 | 12,500 | $1.4M | 19.7% |
| Total | $102.34 avg | 68,056 | $7.0M | 100% |
| Filing → |
| KRYS | SELL | 2025-02-28 | $131K | — | Filing → |
| KRYS | SELL | 2024-03-01 | $1.8M | — | Filing → |
| KRYS | SELL | 2024-03-01 | $1.4M | — | Filing → |